Literature DB >> 9222066

Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.

S K Spangler1, M R Jacobs, P C Appelbaum.   

Abstract

A time-kill method was developed to examine the killing kinetics of trovafloxacin, ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against one strain each of Bacteroides fragilis, Bacteroides thetaiotaomicron, Prevotella melaninogenica, Fusobacterium mortiferum, Peptostreptococcus magnus and Clostridium perfringens. Solutions and suspensions were prepared inside an anaerobic glove box, using syringes and prereduced broth. Bottles were then incubated outside the chamber and viability counts determined after incubation for 0, 6, 24 and 48 h in a shaking water bath, avoiding introduction of air. Bacteriostatic/bactericidal concentrations (mg/L) after 48 h for the six strains were: trovafloxacin, 0.03-1/0.03-1; ciprofloxacin, 0.25-16/0.25-32; sparfloxacin, 0.06-2/0.06-8; metronidazole 1-64/1-64; cefoxitin, 0.125-16/0.125-32; piperacillin, 0.125-64/0.125-64; piperacillin/tazobactam, 0.06-2/0.125-8. Bacteriostatic levels were within two dilutions of broth MICs. By this time-kill method, trovafloxacin had the lowest bacteriostatic concentrations of all compounds tested.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9222066     DOI: 10.1093/jac/39.suppl_2.23

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents.

Authors:  Kim L Credito; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.

Authors:  Dianne B Hoellman; Linda M Kelly; Kim Credito; Lauren Anthony; Lois M Ednie; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 3.  Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.

Authors:  K C Lamp; C D Freeman; N E Klutman; M K Lacy
Journal:  Clin Pharmacokinet       Date:  1999-05       Impact factor: 6.447

4.  Activity of telithromycin (HMR 3647) against anaerobic bacteria compared to those of eight other agents by time-kill methodology.

Authors:  K L Credito; L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

Review 5.  Quinolone activity against anaerobes.

Authors:  P C Appelbaum
Journal:  Drugs       Date:  1999       Impact factor: 9.546

6.  In vitro activities of cefminox against anaerobic bacteria compared with those of nine other compounds.

Authors:  D B Hoellman; S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

7.  Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.

Authors:  M L Peterson; L B Hovde; D H Wright; A D Hoang; J K Raddatz; P J Boysen; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

8.  In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.

Authors:  L E Stearne; C Kooi; W H Goessens; I A Bakker-Woudenberg; I C Gyssens
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

9.  Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis.

Authors:  Kim L Credito; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

10.  Antibacterial Activity against Clinical Isolates and In Vivo Efficacy of Coralmycins.

Authors:  Ha-Young Choi; Bo-Min Kim; Young-Rok Kim; Taehui Yang; Sunjoo Ahn; Dongeun Yong; Jin-Hwan Kwak; Won-Gon Kim
Journal:  Antibiotics (Basel)       Date:  2022-07-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.